Health · Medical Research · 6 hrs ago
Experimental gene therapy shows potential for treating hydrocephalus
Hydrocephalus occurs when too much cerebrospinal fluid builds up in the brain, raising pressure and risking neurological harm.
Current treatment usually involves brain surgery to fit a shunt that drains fluid, but shunts can fail.
Researchers at the University of Cincinnati and the University of California, Davis, tested an experimental gene therapy that targets fluid-producing cells.
In adult animal models with hydrocephalus, the treatment helped prevent excess fluid from entering brain tissue.
The team says it may eventually be delivered less invasively, possibly through an existing shunt, but that approach has not been established for patients.
The findings are an early, preclinical proof of concept, not evidence that the therapy is ready for clinical use.
Further development and safety testing are needed before it could become a treatment option.
Researchers at the University of Cincinnati College of Medicine reported a proof-of-concept study of an experimental gene therapy for hydrocephalus.
The preclinical therapy targets cells that produce cerebrospinal fluid, with the aim of reducing its production.
In adult animal models with induced hydrocephalus, the treatment prevented excess fluid from entering brain tissue outside the ventricles.
The researchers say the approach could offer a less invasive alternative to current treatments, which include shunt surgery.
The findings do not establish that the therapy is safe or effective in people.
- Who
- Researchers at the University of Cincinnati College of Medicine, working with collaborators at the University of California, Davis.
- What
- A preclinical study tested an experimental AAV gene therapy that targets cells producing cerebrospinal fluid.
- When
- The study was recently published; the article was published on 2026-10-14.
- Where
- The research involved the University of Cincinnati and UC Davis; tests were conducted in adult animal models.
- Why
- To explore a potential treatment for hydrocephalus, for which current options include invasive surgery and can be limited.
This story does not have two clearly opposing sides.
The Cincinnati team and UC Davis collaborators tested the experimental gene therapy in adult animal models with induced hydrocephalus.
The preclinical study was published in Fluids and Barriers of the CNS.
- Lead institution
- University of Cincinnati College of Medicine
- Collaborating institution
- University of California, Davis
- Therapy type
- Adeno-associated virus (AAV) gene therapy
- Animal model
- Adult animals with induced hydrocephalus
- Publication
- Fluids and Barriers of the CNS
What people are saying
It efficiently targets the correct cells and reduces CSF production
Hydrocephalus is a life-threatening condition, and our treatment options are surprisingly limited and outdated.
Shunt treatment frequently fails, and alternative endoscopic treatments are not possible for many patients.